AxoGen (NASDAQ:AXGN) Given New $55.00 Price Target at Citizens Jmp

AxoGen (NASDAQ:AXGN) had its target price upped by Citizens Jmp from $50.00 to $55.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has a market outperform rating on the medical equipment provider’s stock.

AXGN has been the subject of several other reports. Raymond James Financial reaffirmed an “outperform” rating and set a $48.00 price objective on shares of AxoGen in a research note on Wednesday, April 29th. Citigroup reissued a “market outperform” rating on shares of AxoGen in a research note on Thursday. Zacks Research upgraded AxoGen from a “strong sell” rating to a “hold” rating in a report on Friday, May 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a $55.00 price target on shares of AxoGen in a research report on Wednesday. Finally, Canaccord Genuity Group increased their price objective on AxoGen from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

AxoGen Stock Down 0.0%

Shares of NASDAQ AXGN opened at $41.35 on Thursday. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08. AxoGen has a 52 week low of $12.39 and a 52 week high of $46.95. The firm’s fifty day moving average is $42.10 and its 200 day moving average is $37.33. The company has a market cap of $2.20 billion, a price-to-earnings ratio of -60.81 and a beta of 1.09.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting the consensus estimate of $0.12. The business had revenue of $69.73 million during the quarter, compared to analysts’ expectations of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 10.13%. On average, equities research analysts expect that AxoGen will post -0.37 earnings per share for the current year.

Insider Activity at AxoGen

In related news, Director Kathy Johnson Weiler sold 16,344 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total value of $720,606.96. Following the completion of the transaction, the director directly owned 16,344 shares of the company’s stock, valued at $720,606.96. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Johnson sold 11,050 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total value of $478,023.00. Following the transaction, the director owned 11,050 shares in the company, valued at $478,023. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 29,041 shares of company stock worth $1,268,792 over the last 90 days. 2.44% of the stock is owned by company insiders.

Institutional Investors Weigh In On AxoGen

Several hedge funds have recently made changes to their positions in the company. MCF Advisors LLC bought a new position in AxoGen in the fourth quarter worth $30,000. Arax Advisory Partners boosted its holdings in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of AxoGen during the 4th quarter valued at $36,000. Kestra Advisory Services LLC bought a new stake in shares of AxoGen during the 4th quarter valued at $39,000. Finally, KBC Group NV purchased a new stake in shares of AxoGen in the 1st quarter worth about $41,000. 80.29% of the stock is currently owned by institutional investors.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: AxoGen raised its 2026 outlook, citing momentum in breast reconstruction and continued demand for its peripheral nerve repair products. The improved outlook suggests management sees stronger revenue potential than previously expected. AxoGen Is Up After Raising 2026 Outlook
• Positive Sentiment: Second-quarter revenue reached $69.73 million, exceeding analyst expectations of $67.10 million. Adjusted earnings of $0.12 per share also topped the Zacks consensus estimate of $0.09 and matched the broader analyst consensus. AxoGen Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Canaccord Genuity raised its price target from $50 to $55 and reiterated a “buy” rating. Citizens JMP also lifted its target to $55 and maintained a “market outperform” rating, signaling increased confidence in AxoGen’s growth prospects. Analyst Price Target Revisions
• Neutral Sentiment: The earnings report showed strong revenue growth, but conference-call commentary highlighted ongoing margin challenges as AxoGen invests for expansion.
• Negative Sentiment: AxoGen continues to report negative profitability metrics, including a net loss and negative net margin and return on equity. Investors may therefore remain focused on whether the stronger outlook translates into sustainable earnings growth.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.